Haverford Trust Company’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $550K | Buy |
+3,944
| New | +$552K | 0.01% | 290 |
|
|
2025
Q3 | – | Sell |
-6,028
| Closed | -$668K | – | 404 |
|
|
2025
Q2 | $668K | Buy |
6,028
+72
| +1% | +$7.66K | 0.01% | 264 |
|
|
2025
Q1 | $667K | Buy |
5,956
+94
| +2% | +$9.7K | 0.01% | 256 |
|
|
2024
Q4 | $541K | Sell |
5,862
-5,753
| -50% | -$518K | 0.01% | 274 |
|
|
2024
Q3 | $974K | Sell |
11,615
-207
| -2% | -$15.8K | 0.01% | 229 |
|
|
2024
Q2 | $811K | Sell |
11,822
-2,235
| -16% | -$149K | 0.01% | 242 |
|
|
2024
Q1 | $1.03M | Buy |
14,057
+772
| +6% | +$59.4K | 0.01% | 216 |
|
|
2023
Q4 | $1.08M | Sell |
13,285
-28
| -0.2% | -$2.18K | 0.01% | 202 |
|
|
2023
Q3 | $998K | Sell |
13,313
-1,440
| -10% | -$111K | 0.01% | 198 |
|
|
2023
Q2 | $1.14M | Sell |
14,753
-8,055
| -35% | -$642K | 0.01% | 196 |
|
|
2023
Q1 | $1.89M | Sell |
22,808
-708
| -3% | -$58.6K | 0.02% | 154 |
|
|
2022
Q4 | $2.02M | Sell |
23,516
-2,455
| -9% | -$194K | 0.02% | 143 |
|
|
2022
Q3 | $1.6M | Sell |
25,971
-4,860
| -16% | -$306K | 0.02% | 152 |
|
|
2022
Q2 | $1.91M | Sell |
30,831
-524
| -2% | -$32.4K | 0.02% | 147 |
|
|
2022
Q1 | $1.86M | Sell |
31,355
-140,660
| -82% | -$8.99M | 0.02% | 150 |
|
|
2021
Q4 | $12.5M | Buy |
172,015
+2,616
| +2% | +$180K | 0.14% | 82 |
|
|
2021
Q3 | $11.8M | Buy |
169,399
+12,352
| +8% | +$868K | 0.14% | 81 |
|
|
2021
Q2 | $10.8M | Buy |
+157,047
| New | +$10.5M | 0.13% | 85 |
|
|
2019
Q1 | – | Sell |
-4,202
| Closed | -$263K | – | 296 |
|
|
2018
Q4 | $263K | Buy |
4,202
+1,154
| +38% | +$80.7K | 0.01% | 248 |
|
|
2018
Q3 | $235K | Sell |
3,048
-560
| -16% | -$42.3K | ﹤0.01% | 271 |
|
|
2018
Q2 | $256K | Buy |
3,608
+360
| +11% | +$25.4K | 0.01% | 252 |
|
|
2018
Q1 | $245K | Sell |
3,248
-250
| -7% | -$19.9K | ﹤0.01% | 262 |
|
|
2017
Q4 | $251K | Sell |
3,498
-3,860
| -52% | -$293K | ﹤0.01% | 255 |
|
|
2017
Q3 | $596K | Sell |
7,358
-2,522
| -26% | -$193K | 0.01% | 171 |
|
|
2017
Q2 | $699K | Buy |
9,880
+3,102
| +46% | +$206K | 0.02% | 156 |
|
|
2017
Q1 | $460K | Sell |
6,778
-783,375
| -99% | -$55.1M | 0.01% | 180 |
|
|
2016
Q4 | $56.6M | Sell |
790,153
-72,244
| -8% | -$5.37M | 1.37% | 29 |
|
|
2016
Q3 | $68.2M | Buy |
862,397
+390,515
| +83% | +$31.7M | 1.7% | 25 |
|
|
2016
Q2 | $39.4M | Buy |
471,882
+24,338
| +5% | +$2.16M | 0.99% | 40 |
|
|
2016
Q1 | $41.1M | Buy |
447,544
+441,433
| +7,224% | +$39.8M | 1.07% | 37 |
|
|
2015
Q4 | $618K | Buy |
6,111
+3,341
| +121% | +$348K | 0.02% | 159 |
|
|
2015
Q3 | $272K | Sell |
2,770
-5
| -0.2% | -$555 | 0.01% | 195 |
|
|
2015
Q2 | $325K | Sell |
2,775
-71
| -2% | -$7.76K | 0.01% | 183 |
|
|
2015
Q1 | $279K | Sell |
2,846
-391
| -12% | -$39.7K | 0.01% | 198 |
|
|
2014
Q4 | $305K | Buy |
3,237
+52
| +2% | +$5.38K | 0.01% | 194 |
|
|
2014
Q3 | $339K | Sell |
3,185
-115
| -3% | -$11.3K | 0.01% | 177 |
|
|
2014
Q2 | $274K | Hold |
3,300
| – | – | 0.01% | 190 |
|
|
2014
Q1 | $234K | Sell |
3,300
-1,760
| -35% | -$138K | 0.01% | 194 |
|
|
2013
Q4 | $380K | Sell |
5,060
-40
| -0.8% | -$2.79K | 0.01% | 200 |
|
|
2013
Q3 | $321K | Sell |
5,100
-2,000
| -28% | -$120K | 0.01% | 160 |
|
|
2013
Q2 | $364K | Buy |
+7,100
| New | +$370K | 0.01% | 166 |
|
Other funds holding GILD
VCM
VPM
Haverford Trust Company's GILD Position: Q1 2026 in Review
Haverford Trust Company opened a new position in Gilead Sciences (GILD) in Q1 2026: 3,944 shares worth $550K. The stake represents 0.01% of the portfolio and ranks #290 among its holdings. This is a return to the name: Haverford Trust Company previously reported a position in GILD as recently as Q2 2025.
Haverford Trust Company first reported a position in GILD in Q2 2013 and has held it in 41 quarters since. The position peaked at $68.2M in Q3 2016. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Haverford Trust Company held 3,944 shares of Gilead Sciences worth $550K as of Q1 2026.
- Gilead Sciences was a new Haverford Trust Company position in Q1 2026.
- Gilead Sciences made up 0.01% of Haverford Trust Company's portfolio in Q1 2026, its #290 holding.
- Haverford Trust Company first reported a position in Gilead Sciences in Q2 2013 and has held it in 41 quarters since.
- Haverford Trust Company's Gilead Sciences position peaked at $68.2M in Q3 2016.
- 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.